NT5C2
Basic information
Region (hg38): 10:103087185-103277605
Previous symbols: [ "NT5B", "SPG45" ]
Links
Phenotypes
GenCC
Source:
- hereditary spastic paraplegia 45 (Strong), mode of inheritance: AR
- hereditary spastic paraplegia 45 (Moderate), mode of inheritance: AR
- hereditary spastic paraplegia 45 (Supportive), mode of inheritance: AR
Clinical Genomic Database
Source:
| Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
|---|---|---|---|---|---|
| Spastic paraplegia 45, autosomal recessive | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Neurologic; Ophthalmologic | 19415352; 24482476 |
ClinVar
This is a list of variants' phenotypes submitted to
- Hereditary_spastic_paraplegia_45 (176 variants)
- Inborn_genetic_diseases (35 variants)
- not_provided (28 variants)
- Hereditary_spastic_paraplegia (8 variants)
- not_specified (5 variants)
- NT5C2-related_disorder (3 variants)
- Neurodevelopmental_disorder (1 variants)
- Microcephaly (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the NT5C2 gene is commonly pathogenic or not. These statistics are base on transcript: NM_001351169.2. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 49 | 50 | ||||
| missense | 66 | 70 | ||||
| nonsense | 8 | |||||
| start loss | 0 | |||||
| frameshift | 7 | |||||
| splice donor/acceptor (+/-2bp) | 10 | |||||
| Total | 19 | 8 | 66 | 51 | 1 |
Highest pathogenic variant AF is 0.000007447902
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| NT5C2 | protein_coding | protein_coding | ENST00000343289 | 17 | 107117 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 0.00000214 | 0.999 | 125688 | 0 | 58 | 125746 | 0.000231 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | 2.64 | 181 | 312 | 0.579 | 0.0000170 | 3714 |
| Missense in Polyphen | 35 | 80.908 | 0.43259 | 1032 | ||
| Synonymous | -0.761 | 117 | 107 | 1.09 | 0.00000513 | 1017 |
| Loss of Function | 2.88 | 15 | 32.8 | 0.458 | 0.00000169 | 408 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.000178 | 0.000177 |
| Ashkenazi Jewish | 0.0000993 | 0.0000992 |
| East Asian | 0.000163 | 0.000163 |
| Finnish | 0.00107 | 0.00106 |
| European (Non-Finnish) | 0.000204 | 0.000202 |
| Middle Eastern | 0.000163 | 0.000163 |
| South Asian | 0.0000655 | 0.0000653 |
| Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: May have a critical role in the maintenance of a constant composition of intracellular purine/pyrimidine nucleotides in cooperation with other nucleotidases. Preferentially hydrolyzes inosine 5'-monophosphate (IMP) and other purine nucleotides.;
- Disease
- DISEASE: Spastic paraplegia 45, autosomal recessive (SPG45) [MIM:613162]: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. Some SPG45 patients manifest mental retardation, contractures and learning disability. {ECO:0000269|PubMed:24482476, ECO:0000269|PubMed:28884889}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Pyrimidine metabolism - Homo sapiens (human);Nicotinate and nicotinamide metabolism - Homo sapiens (human);Purine metabolism - Homo sapiens (human);Purine Nucleoside Phosphorylase Deficiency;Mercaptopurine Action Pathway;Azathioprine Action Pathway;Pyrimidine Metabolism;Nicotinate and Nicotinamide Metabolism;Xanthine Dehydrogenase Deficiency (Xanthinuria);Adenylosuccinate Lyase Deficiency;AICA-Ribosiduria;Thioguanine Action Pathway;Adenine phosphoribosyltransferase deficiency (APRT);Mitochondrial DNA depletion syndrome;Myoadenylate deaminase deficiency;Purine Metabolism;UMP Synthase Deiciency (Orotic Aciduria);MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy);Molybdenum Cofactor Deficiency;Adenosine Deaminase Deficiency;Gout or Kelley-Seegmiller Syndrome;Lesch-Nyhan Syndrome (LNS);Xanthinuria type I;Xanthinuria type II;Beta Ureidopropionase Deficiency;Dihydropyrimidinase Deficiency;Nucleobase catabolism;Metabolism of nucleotides;guanosine nucleotides degradation;Purine metabolism;urate biosynthesis/inosine 5,-phosphate degradation;adenosine nucleotides degradation;purine nucleotides degradation;Vitamin B3 (nicotinate and nicotinamide) metabolism;Abacavir metabolism;Abacavir transport and metabolism;Metabolism;Nicotinate Nicotinamide metabolism;Pyrimidine metabolism;Purine nucleotides nucleosides metabolism;Pyrimidine nucleotides nucleosides metabolism;Purine catabolism
(Consensus)
Recessive Scores
- pRec
- 0.281
Intolerance Scores
- loftool
- 0.657
- rvis_EVS
- -0.2
- rvis_percentile_EVS
- 38.82
Haploinsufficiency Scores
- pHI
- 0.658
- hipred
- Y
- hipred_score
- 0.639
- ghis
- 0.534
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.338
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Nt5c2
- Phenotype
- hematopoietic system phenotype;
Gene ontology
- Biological process
- purine nucleotide catabolic process;phosphorylation;dephosphorylation;drug metabolic process;IMP metabolic process;adenosine metabolic process
- Cellular component
- cytosol
- Molecular function
- nucleotide binding;protein binding;5'-nucleotidase activity;metal ion binding;nucleoside phosphotransferase activity